Bovie Medical Corporation Announces FDA 510(K) Clearance to Market SEER Tissue Resection Device.MELVILLE, N.Y. -- Bovie Medical Corporation (the "Company") (NYSE NYSE See: New York Stock Exchange Alternext US: BVX BVX Bulk Viscosity of Xenon ), a manufacturer and marketer of electrosurgical products, today announced the Company received 510(k) clearance from the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) to market its SEER tissue resection device intended for initial use in liver oncology surgery. The SEER device uses conductive sintered sin·ter n. 1. Geology A chemical sediment or crust, as of porous silica, deposited by a mineral spring. 2. A mass formed by sintering. v. sin·tered, sin·ter·ing, sin·ters v. steel as an electrode for radio frequency (RF) for cutting and coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or .
The process involves delivery of RF current and sterile saline for
resection and coagulation in surgical procedures. The Company
anticipates developing additional products based on the SEER technology
for use in orthopedic and blood vessel blood vesseln. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. sealing procedures. The worldwide market size for the liver and orthopedic market is expected to total $500 million in 2009. Andrew Makrides, president of Bovie stated, "We are pleased to have received FDA 510(k) clearance to market the SEER device in the United States having already CE Marked the product for sale in the European Union. Bovie's ability to market the SEER positions the Company closer to its goal of increasing shareholder value through the development of proprietary technologies and products." For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website www.boviemedical.com. This document may contain some forward looking statements, particularly regarding operational prospects in 2008 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion